---
title: "Gynecologic Oncology"
order: 1
category: "Gynecology"
---

# Gynecologic Oncology

## Overview

Gynecologic oncology encompasses the surgical and medical management of cancers affecting the female reproductive tract, including ovarian, endometrial, cervical, vulvar, and vaginal malignancies. These cancers account for approximately 12% of all female cancers. Surgical management ranges from fertility-sparing procedures in young women to extensive cytoreductive surgery for advanced disease. Modern approaches emphasize minimally invasive techniques when appropriate, sentinel lymph node mapping, and multidisciplinary care including chemotherapy, radiation, and targeted therapies.

### Epidemiology
- **Endometrial cancer**: Most common (67,000 cases/year US)
- **Ovarian cancer**: Highest mortality (13,000 deaths/year)
- **Cervical cancer**: Preventable with HPV vaccination and screening
- **Vulvar/vaginal cancer**: Rare (<10,000 cases/year combined)

## Ovarian Cancer

### Overview
- Fifth leading cause of cancer death in women
- Lifetime risk: 1 in 70 women
- Median age at diagnosis: 63 years
- Most cases diagnosed at advanced stage (75% stage III-IV)
- 5-year survival: 49% overall (93% stage I, 75% stage II, 40% stage III, 17% stage IV)

### Risk Factors
**Increased Risk**:
- Family history (BRCA1/2 mutations, Lynch syndrome)
- Nulliparity
- Early menarche, late menopause
- Endometriosis
- Age
- Ashkenazi Jewish descent

**Decreased Risk**:
- Oral contraceptive use (50% risk reduction with 5 years use)
- Parity
- Breastfeeding
- Tubal ligation
- Hysterectomy

**Genetic Syndromes**:
- **BRCA1**: 40-50% lifetime ovarian cancer risk
- **BRCA2**: 15-25% lifetime ovarian cancer risk
- **Lynch syndrome**: 10-15% lifetime ovarian cancer risk

### Pathology
**Epithelial Tumors** (90%):
- **High-grade serous** (70%): Most common, BRCA association, aggressive
- **Low-grade serous** (5%): Indolent, younger patients
- **Endometrioid** (10%): Associated with endometriosis
- **Clear cell** (10%): Associated with endometriosis, chemoresistant
- **Mucinous** (3%): Often early stage, large tumors

**Germ Cell Tumors** (5%):
- Young women (<30 years)
- Dysgerminoma, yolk sac, teratoma
- Chemosensitive

**Sex Cord-Stromal Tumors** (5%):
- Granulosa cell tumors (hormone-producing)
- Sertoli-Leydig cell tumors

### Presentation
- Abdominal distension, bloating
- Early satiety, dyspepsia
- Pelvic/abdominal pain
- Urinary symptoms
- Ascites
- Adnexal mass on examination
- Often nonspecific symptoms (diagnosis delay)

### Diagnosis and Staging

**Laboratory**:
- **CA-125**: Elevated in 80% of epithelial ovarian cancers
  - Screening not recommended (low specificity)
  - Useful for monitoring treatment response
- **HE4**: Complementary marker
- **CEA, CA 19-9**: Mucinous tumors
- **AFP, β-hCG, LDH**: Germ cell tumors

**Imaging**:
- **Pelvic ultrasound**: Initial evaluation, characterize mass
- **CT chest/abdomen/pelvis**: Staging, assess disease extent
- **MRI**: Characterize indeterminate masses
- **PET/CT**: Optional for treatment planning

**Staging** (FIGO 2014):
- **Stage I**: Confined to ovaries/fallopian tubes
- **Stage II**: Pelvic extension
- **Stage III**: Peritoneal metastases outside pelvis, lymph nodes
- **Stage IV**: Distant metastases (pleural effusion with positive cytology, parenchymal liver/spleen)

### Surgical Management

#### Primary Cytoreductive Surgery

**Goal**: Complete cytoreduction (no visible residual disease)
- Optimal: Residual disease <1cm
- Suboptimal: Residual disease >1cm
- Complete cytoreduction (R0) associated with best survival

**Indications**:
- Suspected ovarian cancer
- Resectable disease at presentation

**Preoperative Preparation**:
- Bowel preparation (mechanical ± antibiotics)
- Thromboprophylaxis
- Type and screen/cross
- Antibiotics (prophylaxis)
- Informed consent (extent of surgery, stoma possibility)

**Surgical Technique**:
1. **Vertical midline incision**: Umbilicus to pubis (adequate exposure)
2. **Cytology**: Peritoneal washings or ascites
3. **Systematic exploration**:
   - Diaphragm, liver, stomach, spleen
   - Bowel (small and large)
   - Omentum
   - Peritoneum (pelvic, paracolic gutters, upper abdomen)
   - Lymph nodes (pelvic, para-aortic)
4. **Total abdominal hysterectomy** (if appropriate):
   - En bloc removal of uterus, cervix
5. **Bilateral salpingo-oophorectomy**:
   - Remove ovaries and fallopian tubes
6. **Omentectomy**:
   - Infracolic or supracolic omentectomy
7. **Lymphadenectomy**:
   - Pelvic nodes (external iliac, internal iliac, obturator, common iliac)
   - Para-aortic nodes (to level of renal vessels)
8. **Peritoneal biopsies/resections**:
   - Pelvic peritoneum
   - Paracolic gutters
   - Diaphragm (stripping if involved)
   - Bladder peritoneum
9. **Appendectomy**: Especially with mucinous histology
10. **Bowel resection**: If involved (low anterior resection, sigmoid, small bowel)
11. **Diaphragm stripping/resection**: If disease present
12. **Splenectomy**: If involved and necessary for complete cytoreduction
13. **Liver resection**: Capsular or wedge resection if achievable

**Fertility-Sparing Surgery** (Highly Selected Cases):
- Young women desiring fertility
- Early stage (IA-IC)
- Low-grade, favorable histology
- **Procedure**: Unilateral salpingo-oophorectomy, staging biopsies, omentectomy, lymphadenectomy
- Close surveillance postpartum, completion surgery after childbearing

**Staging for Early Disease** (Apparent Stage I):
- Peritoneal washings
- Inspection/palpation of all peritoneal surfaces
- Omentectomy
- Pelvic and para-aortic lymphadenectomy
- Random peritoneal biopsies

**Postoperative Care**:
- ICU or floor depending on extent of surgery
- NG tube until bowel function (if extensive bowel resection)
- Foley catheter (remove when ambulatory)
- Early ambulation
- VTE prophylaxis
- Pain management (epidural, PCA, multimodal)
- Monitor for complications
- Pathology review and treatment planning

**Outcomes**:
- Median survival with complete cytoreduction: 40-50 months
- Median survival with optimal (<1cm): 30-36 months
- Median survival with suboptimal (>1cm): 20-24 months
- Complete cytoreduction is strongest prognostic factor

**Complications**:
- Bleeding (transfusion 10-20%)
- Bowel injury/leak (3-5%)
- Ureteral injury (1-2%)
- Bladder injury (1-2%)
- Fistula (vesicovaginal, rectovaginal)
- Infection, abscess
- VTE (despite prophylaxis)
- Prolonged ileus
- Wound dehiscence
- Lymphocele, lymphedema

#### Interval Cytoreductive Surgery

**Indications**:
- Suboptimal primary debulking
- Extensive disease not amenable to complete cytoreduction
- Poor performance status

**Approach**:
- Neoadjuvant chemotherapy (3-4 cycles)
- Interval debulking surgery
- Adjuvant chemotherapy (complete 6 cycles total)

**Outcomes**:
- Equivalent survival to primary cytoreduction in selected patients
- Lower surgical morbidity
- Improved complete cytoreduction rates

#### Secondary Cytoreductive Surgery (Recurrent Disease)

**Indications** (Highly Selected):
- Platinum-sensitive recurrence (>12 months from chemotherapy)
- Complete resection anticipated
- Good performance status
- Isolated recurrence

**Outcomes**:
- Median survival: 30-60 months (if complete cytoreduction achieved)
- Benefit in select patients

### Chemotherapy
- **Adjuvant**: Carboplatin + paclitaxel (6 cycles)
- **Neoadjuvant/adjuvant**: Same regimen for interval debulking
- **Recurrent**: Platinum-sensitive vs. platinum-resistant dictates therapy
- **Intraperitoneal chemotherapy**: Considered for optimally debulked stage III
- **Targeted therapy**: Bevacizumab (anti-VEGF), PARP inhibitors (BRCA mutations)

## Endometrial Cancer

### Overview
- Most common gynecologic malignancy in developed countries
- 67,000 new cases/year in US
- Median age: 60 years (75% postmenopausal)
- 5-year survival: 81% overall (95% stage I, 70% stage III, 17% stage IV)

### Risk Factors
- Obesity (strongest risk factor)
- Unopposed estrogen (HRT, PCOS, anovulation)
- Tamoxifen use
- Nulliparity
- Early menarche, late menopause
- Diabetes, hypertension
- Lynch syndrome (5% of cases)

**Protective**:
- Oral contraceptives
- Parity

### Pathology
**Type I** (80%):
- Endometrioid adenocarcinoma
- Estrogen-related
- Low-grade (Grade 1-2)
- Better prognosis

**Type II** (20%):
- Non-endometrioid (serous, clear cell, carcinosarcoma)
- Not estrogen-related
- High-grade
- Aggressive behavior

**Grading**:
- Grade 1: ≤5% solid growth
- Grade 2: 6-50% solid growth
- Grade 3: >50% solid growth

### Presentation
- Postmenopausal bleeding (90%)
- Abnormal uterine bleeding in premenopausal women
- Abnormal Pap smear (incidental finding)
- Pyometra, hematometra

### Diagnosis
**Endometrial Sampling**:
- **Office endometrial biopsy**: First-line (>90% sensitivity)
- **D&C**: If office biopsy insufficient or stenotic cervix

**Imaging**:
- **Transvaginal ultrasound**: Endometrial thickness (>4mm postmenopausal warrants biopsy)
- **MRI**: Assess myometrial invasion, cervical involvement
- **CT chest/abdomen/pelvis**: Staging if high-grade or advanced stage suspected

**Staging** (FIGO 2009, surgical):
- **Stage IA**: <50% myometrial invasion
- **Stage IB**: ≥50% myometrial invasion
- **Stage II**: Cervical stromal invasion
- **Stage IIIA**: Uterine serosa/adnexa
- **Stage IIIB**: Vaginal/parametrial
- **Stage IIIC**: Pelvic (IIIC1) or para-aortic (IIIC2) lymph nodes
- **Stage IVA**: Bladder/bowel mucosa
- **Stage IVB**: Distant metastases

### Surgical Management

#### Total Hysterectomy with Bilateral Salpingo-Oophorectomy

**Indications**: All stages

**Approach**:
- **Minimally invasive** (laparoscopic or robotic): Preferred for early stage
  - Faster recovery
  - Less pain
  - Equivalent oncologic outcomes to open
- **Open**: Advanced stage, bulky disease, contraindications to MIS

**Technique** (Robotic Total Hysterectomy with BSO):
1. **Port placement**: 4-5 ports
2. **Pelvic exploration**: Assess disease extent
3. **Pelvic washings**: Cytology
4. **Round ligament division**
5. **Bladder flap development**
6. **Utero-ovarian ligament and fallopian tube ligation**
7. **Uterine artery ligation**
8. **Cardinal ligament division**
9. **Colpotomy**: Circumferential incision around cervix
10. **Specimen removal**: Through vagina
11. **Vaginal cuff closure**: Laparoscopically
12. **Oophorectomy**: Remove ovaries and fallopian tubes

**Staging Procedures**:
- **Lymphadenectomy** (pelvic ± para-aortic):
  - Indications: High-grade (grade 3), deep myometrial invasion, cervical involvement, serous/clear cell histology
  - Omit in: Grade 1-2, <50% invasion, tumor <2cm (low-risk)
- **Sentinel lymph node mapping**: Emerging alternative to complete lymphadenectomy
  - Cervical injection of dye (ICG most common)
  - Map and remove sentinel nodes
  - Reduces lymphedema risk
- **Omentectomy**: Serous histology

**Fertility-Sparing** (Highly Selected):
- Grade 1 endometrioid, no myometrial invasion
- Young women desiring fertility
- **Treatment**: High-dose progestins, close surveillance
- Hysterectomy after childbearing

**Postoperative Care**:
- Same-day or 23-hour discharge (minimally invasive)
- 2-3 day stay (open)
- Resume activity in 2 weeks (MIS), 4-6 weeks (open)
- Avoid intercourse until vaginal cuff healed (6-8 weeks)
- Pathology review determines adjuvant therapy

### Adjuvant Therapy
- **Low-risk** (stage IA, grade 1-2): Observation
- **Intermediate-risk** (stage IB, grade 1-2 or stage IA, grade 3): Vaginal brachytherapy
- **High-intermediate risk**: Vaginal brachytherapy ± EBRT
- **High-risk** (stage II, III): EBRT + chemotherapy
- **Advanced/recurrent**: Chemotherapy (carboplatin/paclitaxel), immunotherapy (MSI-high), targeted therapy

### Outcomes
- Stage IA: >95% 5-year survival
- Stage IB: 85-90%
- Stage II: 75-80%
- Stage IIIC: 50-65%
- Recurrence: 10-20% overall

## Cervical Cancer

### Overview
- Preventable disease (HPV vaccination, screening)
- 14,000 new cases/year in US (declining due to screening)
- Developing countries: Higher incidence (lack of screening)
- Median age: 50 years (bimodal: 35-39, 60-64)
- 5-year survival: 66% overall (92% localized, 58% regional, 18% distant)

### Risk Factors
- HPV infection (99% of cases, types 16 and 18 most common)
- Early sexual activity
- Multiple sexual partners
- Immunosuppression (HIV)
- Smoking
- Long-term oral contraceptive use

### Pathology
- **Squamous cell carcinoma** (70%)
- **Adenocarcinoma** (25%)
- **Adenosquamous** (3-5%)
- **Small cell, neuroendocrine** (rare, very aggressive)

### Screening and Prevention
- **HPV vaccination**: Gardasil-9 (9 HPV types), age 9-45 years
- **Screening**: Co-testing (Pap + HPV) or primary HPV testing, age 21-65

### Staging (FIGO 2018, clinical but imaging incorporated)
- **Stage IA**: Microscopic disease (≤5mm depth, ≤7mm width)
  - IA1: ≤3mm depth
  - IA2: >3mm but ≤5mm depth
- **Stage IB**: Visible lesion or >IA2
  - IB1: <2cm
  - IB2: 2-4cm
  - IB3: >4cm
- **Stage II**: Beyond uterus, not to pelvic wall or lower 1/3 vagina
  - IIA: Upper 2/3 vagina
  - IIB: Parametrial invasion
- **Stage III**: Lower 1/3 vagina, pelvic wall, or hydronephrosis
  - IIIA: Lower 1/3 vagina
  - IIIB: Pelvic wall or hydronephrosis
  - IIIC: Lymph node metastases (pelvic IIIC1, para-aortic IIIC2)
- **Stage IV**: Bladder/rectum or distant metastases
  - IVA: Bladder/rectum
  - IVB: Distant metastases

### Surgical Management

#### Cervical Conization

**Indications**:
- Diagnosis of microinvasive disease
- Positive endocervical curettage with no visible lesion
- Adenocarcinoma in situ

**Techniques**:
- **LEEP (Loop Electrosurgical Excision Procedure)**: Office-based
- **Cold knife cone**: Operating room, preferred for adenocarcinoma

**Complications**: Bleeding, cervical stenosis, cervical insufficiency (pregnancy risk)

#### Simple (Extrafascial) Hysterectomy

**Indications**: Stage IA1 without lymphovascular space invasion

**Technique**: Standard total hysterectomy (as described for endometrial cancer)

#### Radical Hysterectomy

**Indications**: Stage IA2-IB2 (some IB3)

**Types**:
- **Type I**: Simple (extrafascial)
- **Type II**: Modified radical (partial parametrium, proximal vagina)
- **Type III**: Radical (entire parametrium to pelvic wall, upper vagina)
- **Type IV**: Extended radical (superior vesical artery, ¾ vagina)

**Radical Hysterectomy (Type III) - Wertheim-Meigs**:

**Approach**: Open, laparoscopic, or robotic

**Technique**:
1. **Pelvic lymphadenectomy**: Complete pelvic and para-aortic (to IMA or renal vessels)
2. **Develop spaces**: Paravesical and pararectal spaces
3. **Identify ureter**: Dissect from medial leaf of broad ligament
4. **Uterine artery ligation**: At origin from internal iliac artery
5. **Bladder mobilization**: Extensive dissection off anterior vagina
6. **Parametrial resection**: Divide at pelvic sidewall (includes uterosacral, cardinal ligaments)
7. **Vaginal resection**: Remove upper 2-3cm of vagina
8. **Specimen removal**: En bloc (uterus, cervix, parametria, upper vagina, ovaries if appropriate)
9. **Vaginal cuff closure**

**Nerve-Sparing Radical Hysterectomy**:
- Identify and preserve pelvic autonomic nerves
- Reduces bladder dysfunction
- Maintains sexual function

**Fertility-Sparing** (Young Women):
- **Radical trachelectomy**: Remove cervix, upper vagina, parametria, preserve uterus
- **Indications**: Stage IA2-IB1 <2cm, desire fertility
- **Approach**: Vaginal or robotic
- **Pregnancy**: Possible but increased preterm delivery risk

**Postoperative Care**:
- Hospital stay: 2-5 days (MIS shorter)
- Foley catheter: May need prolonged (bladder dysfunction common)
- Self-catheterization training if retention
- VTE prophylaxis
- Monitor for complications

**Complications**:
- **Bladder dysfunction** (20-80%): Urinary retention, incontinence
  - Usually temporary, may be prolonged
  - Self-catheterization may be needed
- **Ureteral injury/fistula** (1-2%)
- **Vesicovaginal fistula** (<1%)
- **Lymphedema** (10-20%)
- **Sexual dysfunction**: Vaginal shortening, dyspareunia
- **VTE** (2-5% despite prophylaxis)

#### Pelvic Exenteration

**Indications**:
- Recurrent cervical cancer (central pelvic recurrence)
- Radiation failure
- Bladder or rectal involvement
- No distant metastases

**Types**:
- **Anterior**: Bladder removal, urinary diversion
- **Posterior**: Rectum removal, colostomy
- **Total**: Both bladder and rectum removal

**Technique**: Highly morbid, requires urinary/fecal diversion, vaginal reconstruction

**Outcomes**: 5-year survival 40-60% (if complete resection)

### Primary Radiation Therapy
- **Indications**: Stage IB3-IVA, medically inoperable
- **Technique**: External beam + brachytherapy
- **Chemosensitization**: Concurrent cisplatin
- **Outcomes**: Comparable to surgery for early stage, primary treatment for advanced

### Chemotherapy
- **Concurrent chemoradiation**: Cisplatin weekly
- **Recurrent/metastatic**: Platinum-based doublets, immunotherapy (pembrolizumab for PD-L1 positive)

## Vulvar Cancer

### Overview
- Rare (6,000 cases/year in US)
- Median age: 68 years
- 5-year survival: 71% overall

### Risk Factors
- **HPV-related** (younger women): HPV 16/18, VIN, smoking
- **Non-HPV-related** (older women): Lichen sclerosus, chronic inflammation

### Pathology
- **Squamous cell carcinoma** (90%)
- **Melanoma** (5%)
- **Basal cell carcinoma** (2%)
- **Paget's disease** (1-2%)

### Staging (FIGO 2009, surgical)
- **Stage I**: Confined to vulva/perineum
  - IA: ≤2cm, ≤1mm invasion, node-negative
  - IB: >2cm or >1mm invasion, node-negative
- **Stage II**: Adjacent structures (lower urethra, vagina, anus), node-negative
- **Stage III**: Positive inguinofemoral lymph nodes
- **Stage IV**: Upper urethra, bladder, rectum, distant metastases

### Surgical Management

#### Radical Vulvectomy (Historical)
- En bloc removal of vulva and inguinofemoral lymph nodes
- High morbidity (wound complications, lymphedema, sexual dysfunction)
- **Replaced by**: Modified approaches

#### Modified Radical Vulvectomy with Separate Groin Incisions
- **Tumor excision**: Wide local excision (1-2cm margins)
- **Separate groin incisions**: Inguinofemoral lymphadenectomy through separate incisions
- Reduces wound complications

#### Sentinel Lymph Node Biopsy
- **Indications**: Early stage (T1), unifocal, <4cm, >1mm invasion
- Reduces lymphedema and wound complications
- High negative predictive value

**Technique**:
- Radiolabeled colloid and/or blue dye injection around tumor
- Identify and remove sentinel nodes
- Complete lymphadenectomy if positive

#### Inguinofemoral Lymphadenectomy
- **Indications**: >1mm depth invasion, positive sentinel node
- **Extent**: Superficial and deep inguinal nodes
- **Unilateral vs. bilateral**: Depends on tumor location (midline tumors require bilateral)

**Complications**:
- Wound breakdown (30-50%)
- Lymphedema (20-30%)
- Lymphocele (10-20%)
- Cellulitis/erysipelas

#### Pelvic Exenteration
- Rarely needed for advanced/recurrent disease

### Adjuvant Therapy
- **Radiation**: Positive margins, multiple positive nodes, extracapsular extension
- **Chemoradiation**: Advanced disease

## Vaginal Cancer

### Overview
- Rare (1% of gynecologic cancers)
- Often extension from cervical or vulvar cancer
- Primary vaginal cancer: Must not involve cervix or vulva

### Types
- **Squamous cell carcinoma** (85%)
- **Adenocarcinoma** (10%): Clear cell (DES exposure)
- **Melanoma, sarcoma** (5%)

### Treatment
- **Primary radiation**: Most common treatment (difficult surgical access)
- **Surgery**: Upper vaginal lesions (radical hysterectomy + vaginectomy + lymphadenectomy)
- **Exenteration**: Advanced disease

## Key Points

- Ovarian cancer often presents at advanced stage, complete cytoreduction is key prognostic factor
- Endometrial cancer is most common gynecologic malignancy, minimally invasive surgery is preferred approach
- Sentinel lymph node mapping reduces lymphedema in endometrial and vulvar cancer
- Cervical cancer is preventable through HPV vaccination and screening
- Radical hysterectomy for early cervical cancer includes parametrial and vaginal resection
- Fertility-sparing options available for young women with early-stage disease
- Minimally invasive approaches (robotic, laparoscopic) reduce recovery time with equivalent oncologic outcomes
- Multidisciplinary care essential for optimal outcomes in gynecologic cancers
- Chemotherapy and radiation are important adjuncts to surgery
- Targeted therapies and immunotherapy expanding treatment options

## References

1. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer (2024)
2. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2024)
3. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2024)
4. Society of Gynecologic Oncology Clinical Practice Guidelines (2024)
5. Vergote I, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. N Engl J Med. 2010;363:943-953
